Journal article
Source notes
European Heart Journal · 2020
Bibliographic details
Source record
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Oxford University Press (OUP). 41(24). 2313-2330.
- Study type
- Expert consensus statement and mechanistic evidence review
- Review basis
- Full text reviewed
Artery disease can develop long before someone feels unwell. In an imaging study discussed here, 71% of middle-aged male participants and 43% of female participants had evidence of atherosclerosis before it had become clinically apparent. Atherosclerosis is plaque buildup in artery walls. LDL particles, which carry cholesterol in blood, help drive this process rather than merely signaling that it is happening. Genetic evidence, population observations, and treatment studies together support that causal role. The paper explains how particles enter and become trapped in artery walls, setting off changes that can eventually lead to a heart attack or stroke.
The imaging percentages alone do not prove LDL causes disease; that conclusion rests on several independent kinds of evidence. Once retained, LDL can be modified and provoke inflammation, helping plaques grow and become dangerous. Other particles and the artery wall's response also matter. LDL is therefore a major cause, not a claim that one cholesterol result explains every person's entire cardiovascular risk.
How Does This Show Up in Real Life?
For someone reviewing a cholesterol result, the important question is not simply whether they feel healthy today. The authors emphasize cumulative exposure: both the amount of LDL and how long arteries are exposed to it influence the process. That supports treating prevention as an ongoing issue rather than waiting for symptoms. For people who already have cardiovascular disease and very high risk, the authors discuss maintaining substantial LDL reductions, sometimes with combined treatments. This is not a universal drug plan or a single target for every reader. It can inform a clinical discussion about whether a person's existing prevention plan adequately addresses their risk. A reassuring feeling, or an explanation focused only on inflammation, does not make the causal evidence about LDL disappear.
Important uncertainties remain about why particular plaques progress or respond differently to treatment. Some mechanisms come from cells or animals, and imaging studies do not consistently show every expected plaque change. These gaps concern the details, not whether LDL is causal. The paper does not establish that protection continues unchanged after LDL-lowering treatment is stopped.
Why We Cite It
Alpekin gains a reason to be precise about what a cholesterol measurement represents. LDL cholesterol measures the particles' cholesterol cargo, while the particles themselves vary in composition and behavior. This distinction can improve explanations of biometrics without suggesting that every reader needs specialized particle testing or that all cholesterol-related measurements are interchangeable.
Take this evidence seriously without turning a single result into a personal forecast. It supports prevention directed at an established cause of artery disease. The appropriate treatment, expected benefit, and monitoring still depend on the individual clinical situation, not on a mechanism alone.
Where this source appears